Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US District Court for the Southern District of Florida has ruled that Watson Pharmaceuticals' generic versions of Mucinex, Mucinex D and Mucinex DM (Guaifenesin, Dextromethorphan HBr/ Guaifenesin, and seudoephedrine/Guaifenesin) Extended-Release drugs do not infringe US Patent No 6,372,252.
Subscribe to our email newsletter
The Mucinex products are indicated to loosen phlegm (mucus) and thin bronchial secretions to clear the bronchial passageways of troublesome mucus and make coughs more productive.
Reportedly, in 2009, Reckitt Benckiser filed a suit against Watson for patent infringement related to the generic versions of Mucinex.
Watson Pharmaceuticals is continuing to seek final FDA approval of the products.